Literature DB >> 22941011

Histopathology of hepatocellular carcinoma.

Valérie Paradis1.   

Abstract

Hepatocellular Carcinoma (HCC) is the most frequent primary liver malignancy, mostly occurring in the context of chronic liver diseases leading to cirrhosis. Epidemiological data demonstrate the increasing incidence of HCC worldwide, mainly related to viral hepatitis and metabolic syndrome. Pathological analysis recognizes several types of HCC according to macroscopic and microscopic features. A subset of HCC can develop on normal liver and usually corresponds to specific variants, including fibrolamellar carcinoma mostly encountered in young population. Prognosis of HCC remains poor, depending on delayed tumor diagnosis, the clinical status of the patient but also tumor behavior with a great propensity for angioinvasion.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22941011     DOI: 10.1007/978-3-642-16037-0_2

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  18 in total

1.  Differential Expression of Ion Channels and Transporters During Hepatocellular Carcinoma Development.

Authors:  Violeta Zúñiga-García; María de Guadalupe Chávez-López; Valeria Quintanar-Jurado; Nayeli Belem Gabiño-López; Elisabeth Hernández-Gallegos; Juan Soriano-Rosas; Julio Isael Pérez-Carreón; Javier Camacho
Journal:  Dig Dis Sci       Date:  2015-04-05       Impact factor: 3.199

Review 2.  Liver and Pancreas: Do Similar Embryonic Development and Tissue Organization Lead to Similar Mechanisms of Tumorigenesis?

Authors:  Elsa Ghurburrun; Ivan Borbath; Frédéric P Lemaigre; Patrick Jacquemin
Journal:  Gene Expr       Date:  2018-03-26

3.  MR elastography of hepatocellular carcinoma: Correlation of tumor stiffness with histopathology features-Preliminary findings.

Authors:  Scott M Thompson; Jin Wang; Vishal S Chandan; Kevin J Glaser; Lewis R Roberts; Richard L Ehman; Sudhakar K Venkatesh
Journal:  Magn Reson Imaging       Date:  2016-11-11       Impact factor: 2.546

4.  Predisposing factors for hepatocellular carcinoma recurrence following initial remission after transcatheter arterial chemoembolization.

Authors:  Akitoshi Douhara; Tadashi Namisaki; Kei Moriya; Mitsuteru Kitade; Kosuke Kaji; Hideto Kawaratani; Kosuke Takeda; Yasushi Okura; Hiroaki Takaya; Ryuichi Noguchi; Norihisa Nishimura; Kenichiro Seki; Shinya Sato; Yasuhiko Sawada; Junichi Yamao; Akira Mitoro; Masakazu Uejima; Tsuyoshi Mashitani; Naotaka Shimozato; Soichiro Saikawa; Keisuke Nakanishi; Masanori Furukawa; Takuya Kubo; Hitoshi Yoshiji
Journal:  Oncol Lett       Date:  2017-06-28       Impact factor: 2.967

5.  Environmental exposures as a risk factor for fibrolamellar carcinoma.

Authors:  Rondell P Graham; John R Craig; Long Jin; Andre M Oliveira; John R Bergquist; Mark J Truty; Taofic Mounajjed; Patricia T Greipp; Michael S Torbenson
Journal:  Mod Pathol       Date:  2017-03-03       Impact factor: 7.842

Review 6.  Histopathology of hepatocellular carcinoma.

Authors:  Manuel Schlageter; Luigi Maria Terracciano; Salvatore D'Angelo; Paolo Sorrentino
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

7.  Epigenetic analysis of FHL1 tumor suppressor gene in human liver cancer.

Authors:  Jun Wang; Fang Huang; Jian Huang; Jindan Kong; Shenglan Liu; Jun Jin
Journal:  Oncol Lett       Date:  2017-09-15       Impact factor: 2.967

Review 8.  [Tumor grading of the hepatobiliary system].

Authors:  H Jütte; A Tannapfel
Journal:  Pathologe       Date:  2016-07       Impact factor: 1.011

9.  Hepatocellular carcinoma with both fibrolamellar and classical components: an unusual morphological pattern.

Authors:  Diana Castro-Villabón; Luis E Barrera-Herrera; Paula A Rodríguez-Urrego; Rachel Hudacko; Alonso Vera; Johanna Álvarez; Rafael Andrade; Rocío López
Journal:  Case Rep Pathol       Date:  2015-02-26

Review 10.  Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas.

Authors:  Cindy Neuzillet; Armand de Gramont; Annemilaï Tijeras-Raballand; Louis de Mestier; Jérome Cros; Sandrine Faivre; Eric Raymond
Journal:  Oncotarget       Date:  2014-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.